drugset / Trial / NCT05333549
Istradefylline for Parkinson Disease With Cognitive Impairment
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
Timeline
- Start
- 2022-07-18
- Primary completion
- 2025-06-09
- Completion
- 2025-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 40 mg | — |